person

Magdalena P.

Country
Bulgaria
Department
Women Department with 25 beds; Men Department with 30 beds

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
19
Sites with multiple studies

Has run more than one trial at 19 of 67 partner sites.

Specializations

Psychiatric Disorders

The investigator specializes in treating serious psychiatric conditions, with particular emphasis on bipolar I disorder and schizophrenia. Their research focuses on innovative therapeutic approaches for managing these challenging mental health conditions.

  • Bipolar Mania Management
  • Treatment-Resistant Schizophrenia
  • Antipsychotic Therapy

Their work explores novel therapeutic agents for both acute manic episodes and persistent schizophrenia symptoms.

Therapeutic Interventions

The investigator's expertise extends to evaluating novel therapeutic compounds including lumateperone and valbenazine for psychiatric conditions. Their research encompasses both primary and adjunctive treatment approaches.

  • Novel Psychiatric Medications
  • Adjunctive Therapy Approaches
  • Treatment Response Assessment

Their work involves comprehensive evaluation of medication efficacy, safety, and tolerability in psychiatric populations.

Clinical Assessment

The investigator utilizes specialized clinical assessment tools including the Young Mania Rating Scale to evaluate treatment outcomes. Their approach focuses on measuring therapeutic response in acute and ongoing psychiatric care.

  • Psychiatric Rating Scales
  • Treatment Response Monitoring
  • Safety Assessment Protocols

Their expertise includes systematic evaluation of psychiatric symptoms and treatment effectiveness.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.